Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2011-08-02
2011-08-02
Meller, Michael (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
07989006
ABSTRACT:
Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required.
REFERENCES:
patent: 5157132 (1992-10-01), Tan
patent: 5217992 (1993-06-01), Wright
patent: 5318993 (1994-06-01), Pearce
patent: 5602184 (1997-02-01), Myers
patent: 5660691 (1997-08-01), Barnicki
patent: 5663461 (1997-09-01), Mori et al.
patent: 5756109 (1998-05-01), Burger
patent: 5935581 (1999-08-01), Kapadia et al.
patent: 6083979 (2000-07-01), Sebti
patent: 6239171 (2001-05-01), Lane et al.
patent: 6350453 (2002-02-01), Tan
patent: 6358997 (2002-03-01), Clark
patent: 6441029 (2002-08-01), Elson
patent: 6514531 (2003-02-01), Alaux et al.
patent: 2003/0104090 (2003-06-01), Levy et al.
patent: 2003/0139467 (2003-07-01), Igarashi
patent: 2001114628 (2001-04-01), None
Mercadante et al., Phytochemistry, 52 (1999), 135-139.
Chao et al., Journal of Food Science, vol. 56, No. 1, 1991.
Tanaka et al., Journal of Chromatography, 347, 1985, 275-283.
Adachi, J. and G. Ioannidis (2000). “Glucocorticoid-induced osteoporosis.” Drug Development Research 49: 120-134.
Amin, D., R. Rutledge, et al. (1997). “RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.” J Pharmacol Exp Ther. 281(2): 746-752.
Ayanian, J., C. Fuchs, et al. (1988). “Lovastatin and rhabdomyolysis.” Ann Intern Med. 109: 682-683.
Baker, S. and M. Tarnopolsky (2001). “Statin myopathies: pathophysiologic and clinical perspectives.” Clin Invest Med. 24(5): 258-272.
Ballantyne, C., A. Corsini, et al. (2003). “Risk for myopathy with statin therapy in high-risk patients.” Arch. Intern. Med. 163(5): 553-564.
Bentinger, M., J. Grunler, et al. (1998). “Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase.” Arch Biochem Biophys 353(2): 191-198.
Bliznakov, E. (2002). “Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case—a modern Pandora's box.” Biomed Pharmacother. 56(1): 56-59.
Cenedella, R. (1995). “Role of transcription, translation, and protein turnover in controlling the distribution of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the lens.” Invest Ophthalmol Vis Sci. 36(10): 2133-2141.
Cenedella, R. (1997). “Posttranscriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in lens epithelial cells by mevalonate-derived nonsterols.” Exp Eye Res. 65(1): 63-72.
Chamberlain, L. (2001). “Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes.” FEBS Letters 507(3): 357-361.
Ciosek, C., D. Magnin, et al. (1993). “Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo.” J. Biol. Chem 268: 24832-24837.
Colli, S., S. Eligini, et al. (1997). “Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.” Arterioscler Thromb Vasc Biol 17: 265-272.
Craveiro, A. A., et al., (1989).“The Presence of Geranylgeraniol in Bixa Orelana Linn.,” Quimica Nova, 12(3):297-298.
Cruz, A. and B. Gruber (2002). “Statins and osteoporosis: Can these lipid-lowering drugs also bolster bones?” Cleveland Clinic Journal of Medicine 69(4): 277-288.
Danesi, R., C. McLellan, et al. (1995). “Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation.” Biochem Biophys Res Commun. 206(2): 637-643.
DeFronzo, R. A. (1998). “Pathogenesis of Type 2 Diabetes: Metabolic & Molecular Implications for Identifying Diabetes Genes.” Ann. Rev. Diabetes: 1-93.
Flint, O., B. Masters, et al. (1997). “HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.” Toxicol Appl Pharmacol. 145(1): 99-110.
Flint, O., B. Masters, et al. (1997). “Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.” Toxicol Appl Pharmacol 145(1): 91-98.
Folkers, K., A. Osterborg, et al. (1997). “Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer.” Biochem Biophys Res Commun. 234(2): 296-299.
Gavish, D., E. Leibovitz, et al. (2000). “Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.” J. Intern. med. 247: 563-569.
Grünler, J., J. Ericsson, et al. (1994). “Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins.” Biochim Biophys Acta. 1212(3): 259-77.
Guillet-Deniau, I., et al. (2003). “Glucose induces de novo fatty acid synthesis in rat skeletal muscle through a SREBP-1c dependent pathway.” Diabetes 52(Suppl. 1): extended abstract. 1024P.
Hamilton-Craig, I. (2001). “Statin-associated myopathy.” Med J Aust. 175(9): 486-489.
Haslinger, B., M. Goedde, et al. (2002). “Simvastatin Increases Fibrinolytic Activity in Human Peritoneal Mesothelial Cells Independent of Cholesterol Lowering.” Kidney International 62(5): 1611-1619.
Hevener, A., W. He, et al. (2003). “Muscle-specific Pparg deletion causes insulin resistance.” Nat Med. 9(12): 1491-1497.
Holdaas, H., A. Jardine, et al. (2001). “Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial.” Kidney Int. 60(5): 1990-1997.
Johnston, S. and L. Kelland (2001). “Farnesyl transferase inhibitors—a novel therapy for breast cancer.” Endocr Relat Cancer. 8(3): 227-235.
Jondiko, I. J. O. and Pattenden, G., (1989). “Terpenoids and an Apocarotenoid from Seeds of Bixa Orellana,” Phytochemistry, 28(11):3159-3162.
Judy, W., T. Nguyen, et al. (2004). “Evidence for regression of PSA and tumor size in patients with prostate cancer.” Submitted for publication in Proc. Natl. Acad. Sci.
Kraegen, E. (1998). “Physiologic manifestations of PPAR-gamma activation: preclinical studies.” Clinical Courier 16(48): 5-7.
Lankin, V., A. Tikhaze, et al. (2000). “Intensification in vivo of free radical oxidation of low density lipoproteins in plasma from patients with myocardial ischemia treated by HMG-CoA-reductase pravastatin and suppression of lipid peroxidation by ubiquinone Q10.” Biull Eksp Biol Med. 129(2): 176-179.
Lehmann, J., L. Moore, et al. (1995). “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome p
American River Nutrition, Inc.
Hogan & Lovells US LLP
Meller Michael
LandOfFree
Annatto extract compositions, including geranyl geraniols... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Annatto extract compositions, including geranyl geraniols..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Annatto extract compositions, including geranyl geraniols... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658747